Multi-drug resistant bacteria in China

January 28, 2017
Escherichia coli. Credit: Rocky Mountain Laboratories, NIAID, NIH

The mcr-1 gene—a gene that makes bacteria resistant to colistin, an antibiotic of last resort, and that is transferrable between bacteria—has been found in a wide variety of strains of Escherichia coli in China following widespread use of colistin in agriculture.

As China prepares to introduce the drug for the first time in human medicine, two new studies published in The Lancet Infectious Diseases provide evidence of how widely the mcr-1 gene has spread to bacteria in clinical settings, including to a minority already resistant to the carbapenem class of antibiotics, and highlight the need for caution and careful prescribing when the country introduces colistin.

Infections that are resistant to carbapenems are already common in many countries and in these cases only a small number of antibiotics are effective, including colistin. In 2015, the mcr-1 gene was discovered in China and subsequently identified in other countries including Denmark, Germany, Vietnam, Spain, and the USA among others*, raising fears that bacteria may acquire combined colistin and carbapenem resistance, making them multi-drug resistant.

Two studies published today come at an important time in China. Colistin, which has been used extensively in farming in China since the 1980s, was recently banned for use in agriculture, and will soon be introduced in clinical use for the first time.

The first study, led by Professor Timothy Walsh at Cardiff University (UK) and Professor Jianzhong Shen at the China Agricultural University, looked at the prevalence of bacteria carrying the mcr-1 resistance gene in human infections in two hospitals in Zheijang and Guangdong provinces across 8 years. Among more than 17000 bacterial isolates associated with infection, mcr-1 was detected in 76/5332 samples of E coli and 13/348 samples of Klebsiella pneumoniae. The study is the first to look at risk factors for clinical mcr-1 infection and found that people who had used antibiotics (particularly carbapenems) before hospitalisation were more likely to carry bacteria with the mcr-1 resistance gene. Among 146 isolates of mcr-1-positive E coli identified, only five were also carbapenem resistant.

"The emergence of mcr-1 heralds the breach of the last group of antibiotics, such as colistin. The withdrawal of the drug from agricultural use, and its introduction in the clinic might reduce colistin resistance rates in the community, and increase resistance in hospitals where they may be harder to treat or spread more easily. Our study finds that there are significant risk factors for the spread of mcr-1 infections, beyond just rural living and diet. The spread of colistin resistant bacteria will likely worsen when the drug is introduced in humans," says Professor Tim Walsh.

The second study, led by researchers at Zhejiang University (China), tested samples from over 2000 bloodstream infections at 28 hospitals in China. Of the 1495 E coli samples, 20 were mcr-1 positive, one of which was also carbapenem resistant. Patients with mcr-1-positive infections were all treated successfully with other antibiotics.

"The most troubling problem for clinicians would be the transfer of colistin resistance to a bacterium which is already carbapenem resistant, making it multi-drug resistance. This does not appear to have happened to any great extent in clinical isolates, but the situation should be monitored carefully as the country prepares to introduce colistin for use in humans," says Professor Yunsong Yu, Zhejiang University.

Discussing the findings from both papers in a linked Comment, Professor David Paterson, University of Queensland (Australia) and Associate Professor David van Duin, University of North Carolina (US) write: "at this stage we can conclude that the doomsday scenario of convergence of carbapenem resistance and colistin resistance (via mcr-1) has not yet occurred to any great extent in China. However, prior use of carbapenems was a risk factor for mcr-1 producing E coli, perhaps implying that the intersection between carbapenem resistance and the presence of this colistin mechanism may yet be seen in the future. Furthermore, the spread of mcr-1 into globally widespread and virulent strains of E coli such as ST-131 is cause for ongoing concern and surveillance.

He adds: "After carbapenems, new antibiotics will become available for clinical use in human medicine in China. There are risks that low-cost generic copies of these will be used in agriculture. We must be vigilant to this possibility and urge Chinese authorities to proactively prohibit use of these critical outside of appropriate human use. Without such interventions, there will doubtless be more serious problems than mcr-1 seen in China in the near future."

Explore further: Q&A: Superbug precursor found in US again

More information: The Lancet Infectious Diseases, www.thelancet.com/journals/lan … (16)30528-X/fulltext

* The 2015 research was published in The Lancet Infectious Diseases www.thelancet.com/journals/lan … (15)00424-7/abstract

Related Stories

Q&A: Superbug precursor found in US again

July 11, 2016
A New York City patient was infected with bacteria that had a special type of resistance to antibiotics last year, the earliest known case in the U.S. of bacteria that could lead to a superbug impervious to medications.

More cases of superbug precursor reported, but no spread

September 9, 2016
A fourth U.S. person has been diagnosed with bacteria resistant to a last resort antibiotic, but researchers are expressing relief that so far these superbug precursors have not spread to others.

Colistin-resistant gene detected in the US for the second time

July 11, 2016
For the second time, a clinical isolate of a bacterial pathogen has been detected in humans in the United States which carries the colistin resistance gene, mcr-1. This may also be the first case to show up in the US. That ...

New gene that makes common bacteria resistant to last-line antibiotic found in animals and patients in China

November 19, 2015
A new gene (mcr-1) that enables bacteria to be highly resistant to polymyxins, the last line of antibiotic defence we have left, is widespread in Enterobacteriaceae taken from pigs and patients in south China, including strains ...

ECDC rapid risk assessment outlines actions to reduce the spread of the mcr-1 gene

June 17, 2016
The recently recognised global distribution of the mcr-1 gene poses a substantial public health risk to the EU/EEA. The gene is widespread in several continents and has been detected in bacteria isolated from multiple different ...

Efforts needed to stop the spread of carbapenem-resistant Acinetobacter baumannii

December 14, 2016
ECDC's latest risk assessment highlights the need of increased efforts to face this significant threat to patients and healthcare systems in all EU/EEA countries and outlines options to reduce risks through clinical management, ...

Recommended for you

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

Portable 3-D scanner assesses patients with elephantiasis

October 17, 2017
An estimated 120 million people worldwide are infected with lymphatic filariasis, a parasitic, mosquito-borne disease that can cause major swelling and deformity of the legs, a condition known as elephantiasis. Health-care ...

New tools to combat kidney fibrosis

October 16, 2017
Interstitial fibrosis – excessive tissue scarring – contributes to chronic kidney disease, which is increasing in prevalence in the United States.

How hepatitis C hides in the body

October 13, 2017
The Hepatitis C (HCV) virus is a sly enemy to have in one's body. Not only does it manage to make itself invisible to the immune system by breaking down communication between the immune cells, it also builds secret virus ...

Largest study yet of malaria in Africa shows historical rates of infection

October 12, 2017
(Medical Xpress)—A team of researchers with members from the Kenya Medical Research Institute, the University of Oxford and the University of KwaZulu-Natal has conducted the largest-ever study of the history of malaria ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.